Suppression of acute experimental allergic encephalomyelitis with a small molecule inhibitor of α4 integrin

Multiple Sclerosis

Volumn 11, Issue 6, 2005, Pages 683-690

  Piraino, P S ^a   Yednock, T A ^b   Freedman, S B ^b   Messersmith, E K ^b   Pleiss, M A ^b   Karlik, Stephen J ^a,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ELAN PHARMACEUTICALS   (United States)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

4 integrin; Experimental allergic encephalomyelitis; Magnetic resonance imaging; Multiple sclerosis; Small molecule; Therapeutic

Indexed keywords

ALPHA4 INTEGRIN; ALPHA4 INTEGRIN INHIBITOR; AN 100226M; ANTIALLERGIC AGENT; CT 301; GADOLINIUM; NATALIZUMAB; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CONTRAST MEDIUM EXTRAVASATION; CONTROLLED STUDY; DEMYELINATION; DISSECTION; FEMALE; GUINEA PIG; HISTOPATHOLOGY; IMMUNIZATION; MENINGITIS; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING;

ACUTE DISEASE; ANIMALS; ANTIBODIES; BRAIN EDEMA; CENTRAL NERVOUS SYSTEM; CONTRAST MEDIA; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GADOLINIUM DTPA; GUINEA PIGS; INTEGRIN ALPHA4; MAGNETIC RESONANCE IMAGING; SEVERITY OF ILLNESS INDEX;

EID: 28044467992     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1223oa     Document Type: Article

References (34)

1. Filippi M, Grossman RI. MRI techniques to monitor MS evolution: the present and the future. Neurology 2002; 58: 1147-53.
2. Filippi M, Falini A, Arnold DL, Fazekas F, Gonen O, Simon JH et al. Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group. J Magn Reson Imaging 2005: 21: 669-75.
3. Miller DH, Filippi M, Fazekas F, Frederiksen JL, Matthews PM, Montalban X et al. Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. Ann Neurol 2004; 56: 273-78.
4. O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998; 121: 495-503.
5. Lassmann H, Wekerle H. Experimental models of multiple sclerosis. In Compston A, Ebers G, Lassmann H, McDonald I, Matthews B, Wekerle H eds. McAlpine's multiple sclerosis. London: Churchill Livingstone, 1998: 409-33.
6. Hawkins CP, MacKenzie F, Tofts P, du Boulay EP, McDonald WI. Patterns of blood-brain barrier breakdown in inflammatory demyelination. Brain 1991; 114: 801-810.
7. Namer IJ, Steibel J, Poulet P, Armspach JP, Mohr M, Mauss Y et al. Blood-brain barrier breakdown in MBP-specific T cell induced experimental allergic encephalomyelitis. A quantitative in vivo MRI study. Brain 1993; 116: 147-59.
8. Seeldrayers PA, Syha J, Morrissey SP, Stodal H, Vass K, Jung S et al. Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis. J Neuroimmunol 1993; 46: 199-206.
9. Karlik SJ, Grant EA, Lee D, Noseworthy JH. Gadolinium enhancement in acute and chronic-progressive experimental allergic encephalomyelitis in the guinea pig. Magn Reson Med 1993; 30: 326-31.
10. Namer IJ, Steibel J, Piddlesden SJ, Mohr M, Poulet P, Chambron J. Magnetic resonance imaging of an antibody-mediated demyelinating experimental allergic encephalomyelitis. J Neuroimmunol 1994; 54: 41-50.
11. Morrissey SP, Stodal H, Zettl U, Simonis C, Jung S, Kiefer R et al. in vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema. Brain 1996; 119: 239-48.
12. Karlik SJ, Munoz D, St Louis J, Strejan G. Correlation between MRI and clinico-pathological manifestations in Lewis rats protected from experimental allergic encephalomyelitis by acylated synthetic peptide of myelin basic protein. Magn Reson Imaging 1999; 17: 731-37.
13. Juhler M, Barry DI, Offner H, Konat G, Klinken L, Paulson OB. Blood-brain and blood-spinal cord barrier permeability during the course of experimental allergic encephalomyelitis in the rat. Brain Res 1984; 302: 347-55.
14. Hawkins CP, Munro PM, MacKenzie F, Kesselring J, Tofts PS, du Boulay EP et al. Duration and selectivity of blood-brain barrier breakdown in chronic-relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990; 113: 356-78.
15. Grossman RI, Lisak RP, Macchi PJ, Joseph PM. MR of acute experimental allergic encephalomyelitis. AJNR Am J Neuroradiol 1987; 8: 1045-48.
16. t'Hart BA, Bauer J, Muller HJ, Melchers B, Nicolay K, Brok H et al. Histopathological characterization of magnetic resonance imaging-detectable brain white matter lesions in a primate model of multiple sclerosis: a correlative study in the experimental autoimmune encephalomyelitis model in common marmosets (Callithrix jacchus). Am J Pathol 1998; 153: 649-63.
17. Kuharik MA, Edwards MK, Farlow MR, Becker GJ, Azzarelli B, Klatte EC et al. Gd-enhanced MR imaging of acute and chronic experimental demyelinating lesions. AJNR Am J Neuroradiol 1988; 9: 643-48.
18. 1 integrin. Nature 1992; 356: 63-66.
19. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of alpha 4 integrin by CD4 cells is required for their entry into brain parenchyma. J Exp Med 1993; 177: 57-68.
20. Soilu-Hanninen M, Roytta M, Salmi A, Salonen R. Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. J Neuroimmunol 1997; 72: 95-105.
21. 4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. PNAS 1999; 96: 6896-901.
22. 4 integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pig. J Magn Reson Imaging 1995; 5: 535-40.
23. 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58: 1-10.
24. 4 integrin throughout active experimental allergic encephalomyelitis. Neurology 1996; 47: 1053-59.
25. Leger OJ, Yednock TA, Tanner L, Horner HC, Hines DK, Keen S et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997; 8: 3-16.
26. 4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466-72.
27. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA et al. A controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
28. Jackson DY. Alpha 4 integrin antagonists. Curr Pharm Des 2002; 8: 1229-53.
29. Kuchroo VK, Martin CA, Greer JM, Ju ST, Sobel RA, Dorf ME. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J Immunol 1993; 151: 4371-82.
30. 7-integrin. J Clin Invest 1998; 102: 2096-105.
31. 4 integrins on experimental allergic encephalomyelitis in Lewis rats. J Neurosci Res 2002; 67: 191-99.
32. 4 integrin. J Neuroimmunol 2002; 131: 147-59.
33. Bastianello S, Pozzilli C, Bernardi S, Bozzao L, Fantozzi LM, Buttinelli C et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 1990; 40: 591-95.
34. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990; 113: 1477-89.